Urological Research

, Volume 33, Issue 6, pp 465–469 | Cite as

Elevated plasma concentrations of transforming growth factor-beta 1 in patients with unilateral ureteral obstruction

  • Hakan Vuruskan
  • Zulkuf Caliskan
  • Yakup Kordan
  • Cuneyt Ozakin
  • Ismet Yavascaoglu
  • Bulent Oktay
Original Paper
First Online:
Received:
Accepted:

Abstract

We measured plasma concentrations of TGF-beta 1 in patients with obstructive ureteral calculi and compared them with the plasma concentrations of healthy volunteers. The present study was a prospective study containing a homogenous group of patients with unilateral ureteral obstruction (UUO). The study consisted of patients with ureteral stones less than 7 mm in diameter that caused mild to moderate obstruction. All patients were referred by the emergency department of our hospital and examined between April 2003 and April 2004. The presence and characteristics of both stone and obstruction were determined by plain abdominal x-ray and gray-scale ultrasonography (US). Blood samples were collected from both patients and control individuals on admission and 1 week after conservative follow-up. The plasma TGF-beta 1 concentration was determined using a quantitative sandwich enzyme immunoassay specific for TGF-beta 1. There were 35 patients with 20 women and 15 men (average age 26.8±5.9 years), and 15 volunteers in the control group, with nine women and six men (average age 24.2±4.5 years). Average stone size was 5.6 mm±1.2 mm (range 3.5–7) for the patient group. US showed the presence of mild hydronephrosis in 24 and moderate hydronephrosis in 11 patients. Plasma concentrations of TGF-beta 1 in patients with ureteral obstruction (1,117±5.8 ng/ml, range 36–2,442 ng/ml) were significantly higher than those in the healthy control group (32±4 ng/ml) on admission (P<0.001). There was a significant increase in TGF-beta 1 plasma concentrations in the patient group (33,525±6.8 ng/ml, range 1,107–73,288 ng/ml) after 1 week follow-up (P<0.001). Ureteral obstruction increases plasma TGF-beta 1 concentrations in patients with ureteral stones as in UUO models in animal studies. A concomitant treatment with an anti-fibrotic agent may reduce the incidence of renal injury during obstruction.

Keywords

TGF-beta 1 Obstructive nephropathy Ureteral calculus Interstitial fibrosis 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgment

This study was performed with financial support from the Research Foundation of Uludag University from Bursa, Turkey.

References

  1. 1.
    Hubner WA, Irby P, Stoller ML (1993) Natural history and current concepts for the treatment of small ureteral calculi. Eur Urol 24: 172PubMedGoogle Scholar
  2. 2.
    Ueno A, Kawamura T, Ogawa A, Takayasu H (1977) Relation of spontaneous passage of ureteral calculi to size. Urology 10: 544CrossRefPubMedGoogle Scholar
  3. 3.
    Klahr S (2001) Urinary tract obstruction. Semin Nephrol 21: 133CrossRefPubMedGoogle Scholar
  4. 4.
    Sharma K, Ziyadeh FN (1994) The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 266: 829Google Scholar
  5. 5.
    Ito K, Chen J, El Chaar M et al. (2004) Renal damage progresses despite improvement of renal function after relief of UUO in adult rats. AJP Renal Physiol 287: 1283CrossRefGoogle Scholar
  6. 6.
    Shokeir AA, Provoost AP, Nijmaan RJM (1999) Recoverability of renal function after relief of chronic partial upper urinary tract obstruction. BJU Int 83: 11CrossRefPubMedGoogle Scholar
  7. 7.
    Manucha W, Oliveros L, Carrizo L, Seltzer A, Valles P (2004) Losartan modulation on isoforms and COX-2 expression in early renal fibro genesis in unilateral obstruction. Kidney Int 65: 2097CrossRefGoogle Scholar
  8. 8.
    Mizuguchi Y, Miyajima A, Kosaka T et al. (2004) Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. J Urol 172: 2456CrossRefPubMedGoogle Scholar
  9. 9.
    Ishidoya S, Morrisey J, McCracken R, Reyes A, Klahr S (1995) Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47: 1285PubMedGoogle Scholar
  10. 10.
    Kaneto H, Morrisey J, Klahr S (1993) Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 44: 313PubMedGoogle Scholar
  11. 11.
    Oka A, Toshino N, Miyauchi A, Yokoyama M (1999) Expression of growth factors after release of ureteral obstruction in the rat kidney. Int J Urol 6: 607CrossRefPubMedGoogle Scholar
  12. 12.
    Malave SR, Neiman HL, Spies SM et al. (1980) Diagnosis of hydronephrosis: comparison of radionuclide scanning and sonography. Am J Roentgenol 135: 1179Google Scholar
  13. 13.
    Ulm AH, Miller F (1962) An operation to produce experimental reversible hydronephrosis in dogs. J Urol 8: 261Google Scholar
  14. 14.
    Klahr S (1991) New insights into the consequences and mechanisms of renal impairment in obstructive nephropathy. Am J Kidney Dis 18: 689PubMedGoogle Scholar
  15. 15.
    Nagle RB, Bulger RE, Cutler RE, Jervis HR, Benditt EP (1973) Unilateral obstructive nephropathy in the rabbit. I. Early morphologic, physiologic and histochemical changes. Lab Invest 28: 456PubMedGoogle Scholar
  16. 16.
    Roberts AB, McCune BK, Sporn MB (1992) TGF-Beta regulation of extracelluler matrix. Kidney Int 41: 557PubMedGoogle Scholar
  17. 17.
    Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo NC (1994) Macrophages, monocyte chemoattractant peptide-1 and TGF-beta 1 in experimental hydronephrosis. Am J Physiol 266: 926Google Scholar
  18. 18.
    Bole A, Mackensen-Haen S, Von Gisse H (1987) Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol 17: 421Google Scholar
  19. 19.
    Wen JG, Frokier J, Jorgensen TM, Djurhuus JC (1999) Obstructive nephropathy: an update of the experimental research. Urol Res 27: 29CrossRefPubMedGoogle Scholar
  20. 20.
    Carr MC, Peters CA, Retik AB, Mandell J (1994) Urinary levels of the renal tubular enzyme N-acetyl-glucosaminidase in unilateral obstructive uropathy. J Urol 151: 442PubMedGoogle Scholar
  21. 21.
    Huland H, Gonnermann D, Werner B, Possin U (1998) A new test to predict reversibility of hydronephrotic atrophy after stable partial unilateral ureteral obstruction. J Urol 140: 1591Google Scholar
  22. 22.
    Assimos DG, Boyce WH, Furr EG et al. (1987) Urinary enzyme levels after extracorporeal shock wave lithotripsy (ESWL). J Urol [Suppl] 137: 143AGoogle Scholar
  23. 23.
    Ogata Y, Ishidoya S, Fukuzaki A et al. (2002) Upregulated expression of transforming growth factor-beta, type IV collagen and plasminogen activator inhibitor-1 mRNA are decreased after release of unilateral ureteral obstruction. Tohoku J Exp Med 197: 159CrossRefPubMedGoogle Scholar
  24. 24.
    Fukuda K, Yoshitomi K, Yanagida T, Tokumoto M, Hirakata H (2001) Quantification of TGF-Beta 1 mRNA along rat nephron in obstructive nephropathy. Am J Physiol Renal Physiol 281: 513Google Scholar
  25. 25.
    Xie Y, Sakatsume M, Nishi S et al. (2001) Expression, roles, receptors and regulation of osteopontin in the kidney. Kidney Int 60: 1645CrossRefPubMedGoogle Scholar
  26. 26.
    Giachelli CM, Pichler R, Lombardi D et al. (1994) Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 45: 515PubMedGoogle Scholar
  27. 27.
    Umekawa T, Hatanaka Y, Kurita T, Khan SR (2004) Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J Am Soc Nephrol 15: 635CrossRefPubMedGoogle Scholar
  28. 28.
    Ellenbogen PH, Scheible FW, Talner LB et al. (1978) Sensitivity of gray scale ultrasound in detecting urinary tract obstruction. Am J Roentgenol 130: 731Google Scholar
  29. 29.
    Baumgartner BR, Steinberg HV, Ambrosse SS et al. (1987) Sonographic evaluation of renal stones treated by extracorporeal shock-wave lithotripsy. Am J Roentgenol 149: 131Google Scholar
  30. 30.
    Border WA, Noble NA (1993) Cytokines in kidney disease: the role of transforming growth factor-beta. Am J Kidney Dis 22: 105PubMedGoogle Scholar
  31. 31.
    Hankonen E, Teppo AM, Tornroth H, Groop PA, Gronhagen-Riska C (1997) Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant 12: 2562CrossRefPubMedGoogle Scholar
  32. 32.
    Hellmich B, Scheller M, Schatz H, Pfeiffer A (2000) Activation of transforming growth factor-beta 1 in diabetic kidney disease. Metabolism 49: 353CrossRefPubMedGoogle Scholar
  33. 33.
    Boratynska M (1999) Urine excretion of transforming growth factor-beta 1 in chronic allograft nephropathy. Ann Transplant 2: 23Google Scholar
  34. 34.
    Haramaki R, Tamaki K, Fujisawa M et al. (2001) Steroid therapy and urinary transforming growth factor-beta 1 in Ig-A nephropathy. Am J Kidney Dis 38: 1191PubMedGoogle Scholar
  35. 35.
    De Muro P, Faedda R, Freso P et al. (2004) Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res 49: 293CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Hakan Vuruskan
    • 1
  • Zulkuf Caliskan
    • 1
  • Yakup Kordan
    • 1
  • Cuneyt Ozakin
    • 2
  • Ismet Yavascaoglu
    • 1
  • Bulent Oktay
    • 1
  1. 1.Department of UrologyMedical Faculty
  2. 2.Department of MicrobiologyMedical Faculty

Personalised recommendations